secwatch / observer
8-K filed November 2, 2023, 7:59 PM ET ticker GYRE CIK 0001124105
other material confidence high sentiment neutral materiality 0.60

GYRE THERAPEUTICS, INC. (GYRE): auditor change — Gyre Therapeutics dismisses auditor EisnerAmper, engages Grant Thornton; CEO and CFO exit

GYRE THERAPEUTICS, INC.

item 4.01item 5.02item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Nassim Usman

President and Chief Executive Officer
GYRE · GYRE THERAPEUTICS, INC.
Effective
2023-10-30
Filed
November 2, 2023, 7:59 PM ET
Nassim Usman, Ph.D., Catalyst’s President and Chief Executive Officer, ceased to be an officer of Gyre
Departed (interim)

Seline Miller

Interim Chief Financial Officer
GYRE · GYRE THERAPEUTICS, INC.
Effective
2023-10-30
Filed
November 2, 2023, 7:59 PM ET
Seline Miller, Catalyst’s Interim Chief Financial Officer, ceased to be an officer of Gyre

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

GYRE THERAPEUTICS, INC. dismissed EisnerAmper LLP as its auditor.

Action
dismissal
Auditor
EisnerAmper LLP
Successor
Grant Thornton Zhitong Certified Public Accountants LLP
Exact text from the filing
(a) Dismissal of Independent Registered Public Accounting Firm Prior to the Closing Date, EisnerAmper LLP (“EisnerAmper”) served as the independent registered public accounting firm of Catalyst. On the Closing Date, following the completion of Catalyst’s audit for the year ended December 31, 2022 and the subsequent interim periods through September 30, 2023, which consisted only of the accounts of Catalyst, and the filing of Catalyst’s Annual Report on Form 10-K for the year ended December 31, 2022 and Catalyst’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2023, June 30, 2023 and September 30, 2023, the Audit Committee (the “Audit Committee”) of Gyre’s board of directors dismissed EisnerAmper as Gyre’s independent registered public accounting firm.
View on SEC.gov
Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

GYRE THERAPEUTICS, INC. engaged Grant Thornton Zhitong Certified Public Accountants LLP as its auditor.

Action
engagement
Auditor
Grant Thornton Zhitong Certified Public Accountants LLP
Exact text from the filing
(b) Engagement of Independent Registered Public Accounting Firm On the Closing Date, the Audit Committee engaged Grant Thornton Zhitong Certified Public Accountants LLP (“Grant Thornton”) as Gyre’s independent registered public accounting firm.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Nassim Usman departed as President and Chief Executive Officer at GYRE THERAPEUTICS, INC..

Action
ceased to be an officer
Role
President and Chief Executive Officer
Exact text from the filing
Nassim Usman, Ph.D., Catalyst’s President and Chief Executive Officer, ceased to be an officer of Gyre
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Seline Miller departed as Interim Chief Financial Officer at GYRE THERAPEUTICS, INC..

Action
ceased to be an officer
Role
Interim Chief Financial Officer
Exact text from the filing
Seline Miller, Catalyst’s Interim Chief Financial Officer, ceased to be an officer of Gyre
View on SEC.gov

19 auditor changes filed in the last 30 days. Browse all auditor changes →

GYRE THERAPEUTICS, INC. filing history →

Source: SEC EDGAR
accession 0001140361-23-051195
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.